Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
gptkb:BAY_223
|
| gptkbp:CASNumber |
1802002-99-2
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Bayer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bay 223
|
| gptkbp:indication |
prostate cancer
|
| gptkbp:mechanismOfAction |
PSMA-targeted radioligand therapy
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
prostate-specific membrane antigen
|
| gptkbp:bfsParent |
gptkb:Sofitel_San_Francisco_Bay
|
| gptkbp:bfsLayer |
6
|